References

PsP

  1. Kleinsmith L-J., Kerrigan D., Kelly J., Hollen B. 2004. Understanding Cancer. National Cancer Institute.
  2. Wilment J.A., Gordon S., Brown G.D. 2001. Characterization of the Human β-Glucan Receptor and Its Alternatively Spliced Isoforms. The Journal of Biological Chemistry. 276 (47) : 43818-43823.
  3. Chan G.F-C., Chan W.K., Sze D.M-Y. 2009. The Effects of β-Glucan on Human Immune and Cancer Cells. Journal of Hematology & Oncology. 2 (25) : 1-11.
  4. Cao Q. Z., Lin Z.B. 2004. Antitumor and Anti-Angiogenic Activity of Ganoderma lucidum Polysaccharide peptide. Acta Pharmacol Sin. 25 (6) : 833-838.
  5. Li W-D., Zhang B-D., Wei R., Liu J-H., Lin Z.B. 2008. Reversal Effect of Ganoderma lucidum Polysaccharide on Multidrug Resistance in K562/ADM Cell Line. Acta Pharmacol Sin. 29 (5) : 620-627.
  6. Sadava D., Still D.W., Mudry R.R., Kane S.E. 2009. Effect of Ganoderma on Drug-Sensitive and Multidrug-Resistant Small Cell Lung Carcinoma Cells. Cancer Letters. 277 : 182-189.
  7. Weitberg A.B. 2008. A Phase I/II Trial of Beta-(1,3)/(1,6)-D-Glucan in the Treatment of Patients with Advanced Malignancies Receiving Chemotherapy. Journal of Experimental and Clinical Cancer Research. 27 (40) : 1-4.
  8. Zhu X-L., Liu J-H., Li W-D., Lin Z-B. 2012. Promotion of myelopoiesis in myelosuppressed mice by Ganoderma lucidum polysaccharides. Ethnopharmacology. 3 (20) : 1-7.
  9. Chen W-C., Hau D-M., Wang C-H., Lin I-H., Lee S-S. 1995. Effects of Ganoderma lucidum and Krestin on Subset T-Cell in Spleen of γ-irradiated Mice. American Journal of Chinese medicine. 23 : 289-298.
  10. Brashers V.L. 2006. Pathophysiology. The Biologic Basis for Disease in Adults and Children. 5th Edition. Chapter 30: Alterations of Cardiovascular Function. Elsevier Mosby : 1081-1146.
  11. Aarsaether E., Rydningen M., Engstad R.E., Busund R. 2006. Cardioprotective Effect of Pretreatment with                 β-Glucan in Coronary Artery Bypass Grafting. Scandinavian Cardiovascular Journal. 40 : 298-304.
  12. Li C., Ha T., Kelley J., Gao X., Qiu Y., Kao R.L., Browder W., Williams D.L. 2004. Modulating Toll-like Receptor Mediated Signaling by (1®3)-β-D-Glucan Rapidly Induces Cardioprotection. Cardiovascular Research. 61 : 538-547.
  13. Sargowo D., Widodo M.A., Wihastuti T.A., 2013. Laporan Penelitian : Pengembangan Potensi Peptida Polisakarida (Ganoderma lucidum) sebagai Antioksidan dan Antiinflamasi pada Model In Vivo Atherosclerosis. Fakultas Kedokteran Universitas Brawijaya.
  14. Sargowo D., Widodo M.A., Wihastuti T.A., 2013. Laporan Penelitian : Pengembangan Potensi Peptida Polisakarida (Ganoderma lucidum) sebagai Antioksidan dan Antiinflamasi pada Model In Vivo Diabetes Mellitus Tipe II. Fakultas Kedokteran Universitas Brawijaya.
  15. Ross G.D. 2005. Effect of Glucan on Stem Cell Recruitment and Tissue Repair. World Intellectual Property Organization. WO 2005/084692 A2.
  16. Gao Y., Zhou S., Chen G., Dai X., Ye J., Gao H. 2002. A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis B. International Journal of Medicinal Mushrooms. 4: 321-327.
  17. Gao Y., Zhou S., Huang M and Xu A. 2003. Antibacterial and Antiviral Value of the Genus Ganoderma P. Karst Species (Aphyllophoromycetideae): A Review. International Journal of Medicinal Mushrooms. 5 : 235-246.
  18. Park E-J, Ko G, Kim J, Sohn D.H. 1997. Antifibrotic Effects of a Polysaccharide Extracted from Ganoderma lucidum, Glycirrhizin, and Pentoxifylline in Rats with Cirrhosis Induced by Biliary Obstruction. Biol. Pharm. Bull. 20 (4) : 417-420.
  19. Falanga V. 2005. Wound Healing and Its Impairment in the Diabetic Foot. Lancet. 366 : 1736-43.
  20. Maruyama K., Asai J., Li M., Thorne T., Losondo D.W., D’Amore P.A. 2007. Decreased Macrophage Number and Activation Lead to Reduce Lymphatic Vessel Formation and Contribute to Impaired Diabetic Wound Healing. The American Journal of Pathology. 170 : 1178-1191.
  21. Wei D., Zhang L., Williams D.L., Browder I.W. 2002. Glucan Stimulates Human Dermal Fibroblast Collagen Biosynthesis through a Nuclear Factor-1 Dependent Mechanism. Wound Repair and Regeneration. 10 : 161-168.
  22. Kougias P., Wei D., Rice P.J., Ensley H.E., Kalbfleisch J., Williams D.L and Browder I.W. 2001. Normal Human Fibroblast Express Pattern Recognition Receptors for Fungal (1®3)-β-D-Glucans. Infection and Immunity. 69 (6) : 3933-3938.
  23. Wei D., Williams D., Browder W. 2002. Activation of AP-1 and SP1 Correlates with Wound Growth Factor Gene Expression in Glucan-treated Human Fibroblast. International Immunopharmacology. 2 : 1163-1172.
  24. Berdal M., Appelbom H.I., Eikrem J.H., Lund A., Zykova S., Busund L-T., Setjelid R., Jenssen T. 2007. Aminated β-1,3-D-Glucan Improves Wound Healing in Diabetic db/db Mice. Wound Repair and Regeneration. 15 : 825-832.

  1. Kleinsmith L-J., Kerrigan D., Kelly J., Hollen B. 2004. Understanding Cancer. National Cancer Institute.
  2. Bergers G., Benjamin L.E. 2003. Tumorigenesis and the Angiogenic Switch. Nature Reviews. 3: 401-410.
  3. Beliveau R., Gingras D., Kruger E.A., Lamy S., Sirois P., Simard B., Sirois M.G., Tranqui L., Baffert F., Beaulieu E., Dimitriadou V., Pepin M.C., Courjal F., Ricard I., Poyet P., Falardeau P., Figg W.D., and Dupont E. 2002. The Antiangiogenic Agent Neovastat (AE-941) Inhibits Vascular Endothelial Growth Factor-mediated Biological Effects. Clinical Cancer Research. 8 : 1242-1250.
  4. Gingras D., Renaud A., Mousseau N., Beaulieu E., Kachra Z., Beliveau R. 2001. Matrix Proteinase Inhibition by AE-941, a Multifunctional Antiangiogenic Compound. Anticancer Research. 21 : 145-146.
  5. Sander D.N., DeKoven J., Champagne P., Croteau D., Dupont E. 2002. Neovastat (AE-941), an Inhibitor of Angiogenesis : Randomized Phase I/II Clinical Trial Results in Patients with Plaque Psoriasis. J. Am. Acad. Dermatol. 47 (4) : 535-541. 

THYMUS 3

  1. Low T.L.K., Goldstein A.L., 1985. Thymic Hormones : An Overview. Methods in Enzymology. 116 : 213-219.
  2. Wilson J.L. 1999. Thymus Extracts : An International Literature Review of Clinical Studies. Foundation for Immunology and Nutrition, Development, Education and Research.
  3. Fan Y-Z., Chang H., Yu Y., Liu J., Wang R. 2006. Thymosin α1 Suppresses Proliferation and Induces Apoptosis in Human Leukemia Cell Lines. Peptides. 27 : 2265-2173.
  4. Gish R.G., Gordon S.C., Nelson D., Rustgi V., Rios I. 2009. A Randomized Controlled Trial of Thymalfasin plus Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma. Hepatol Int. 3 : 480-489.
  5. Kerrebijn J.D., Simons P.J., Tas M., Balm A.J.M., Prexhage H.A. 1995. In Vivo Effects of Thymostimulin Treatment on Monocyte Polarization, Dendritic Cell Clustering and Serum p15E-like trans-membrane Factors in Operable Head and Neck Squamous Cell Carcinoma Patients. Eur Arch Otorhinolaryngol. 252 : 409-416.
  6. You J., Zhuang L., Chen H-Y., Yan S-M., Yu L., Huang J-H., Tang B-Z., Huang M-L., Ma Y-L., Chongsuvivatwong V, Sriplung H., Geater A., Qiao Y-W., Wu-R.X. 2006. Efficacy of Thymosin Alpha-1 and Interferon Alpha in Treatment of Chronic Viral hepatitis B : A Randomized Controlled Study. World J Gastroenterol. 12 (41) : 6715-6721.

Fellafit

  1. Bonnet C.S and Walsh D.A. 2005. Osteoarthritis, Angiogenesis and Inflammation. Rheumatology. 44 : 7-16.
  2. Syme B.A. The Therapeutic Efficacy of Shark Cartilage Extract in Treating Canine Degenerative Joint Disease. Vets All Natural Animal Health Centre.
  3. Kelly G.S. 1998. The Role of Glucosamine Sulfate and Chondroitin Sulfate in the Treatment of Degenerative Joint Disease. Alternative Medicine Review. 3 (1) : 27-39.
  4. Mucci A., Schenetti L., Volpi N. 2000. 1H and 13C Nuclear Magnetic Resonance Identification and Characterization of Components of Chondroitin Sulfate of Various Origin. Carbohydrate Polymers. 41 : 37-45.
  5. Ronca F., Palmieri L., Panicucci P., Ronca G. 1998. Anti-Inflammatory Activity of Chondroitin Sulfate. Osteoarthritis Cartilage. 6 (Suppl.A) : 14-21.
  6. IBSA. 2003. Structure-modifying Drugs for Osteoarthritis.The Role of Chondroitin 4 & 6 Sulfate. Osteoarthritis and Cartilage. 7 : 5-16.
  7. Nadanaka S., Clement A., Masayama K., Faissner A., Sugahara K. 1998. Characteristic Hexasaccharide Sequences in Octasaccharides Derived from Shark Cartilage Chondroitin Sulfate D with a Neurite Outgrowth Promoting Activity. Journal of Biological Chemistry. 273 (6) : 3296-3307.
  8. Glade M.J. 1990. Polysulfated Glycosaminoglycan Accelerates Net Synthesis of Collagen and Glycosaminoglycans by Arthritic Equine Cartilage Tissue and Chondrocytes. Am J Vet Res. 51 : 779-785.
  9. Nishimura M., Yan W., Mukudai Y., Nakamura S., Nakamasu K., Kawata M., Kawamoto, Mitsuhide N.,            Hamada T., Kato Y. 1998. Role of Chondroitin Sulfate-Hyaluronan Interactions in the Viscoelastic Properties of Extracellular Matrices and Fluids. Biochimica et Biophysica Acta. 1380 : 1-9.
  10. Wong K.P and Liang J.H. 2000. The Characterization of Angiogenesis Inhibitor from Shark Cartilage. Angiogenesis : from the Molecular to Integrative Pharmacology : 209-223.
  11. Simanek V., Kren V., Ulrichova J., Gallo J. 2005. The Efficacy of Glucosamine and Chondroitin Sulfate in the Treatment of Osteoarthritis : Are these Saccharides Drugs or Nutraceuticals ?. Biomed Papers. 149 (1) : 51-56.

  1. Burdock G.A. 1998. Review of the Biological Properties and Toxicity of Bee Propolis (Propolis). Food and Chemical Toxicology. 36 : 347-363.
  2. Grange J.M and Davey R.W. 1990. Antibacterial Properties of Propolis. Journal of the Royal Society of Medicine. 83.
  3. Study of The Use of BIO-PROLIS as Palliative Approachment for Cancer in Palliative Clinic  Dr. Soetomo Hospital- Faculty of Medicine Airlangga University. 2006. Research Department of Indonesian Palliative Society, East Java Branch.

pdf-icon Download PDF